Intermittent chemotherapy can retain the therapeutic potential of anti-CD137 antibody during the late tumor-bearing state.
Bottom Line: Although a significant antitumor effect was observed when local anti-CD137 mAb therapy (5 μg) was started early in the tumor-bearing stage (day 10), no therapeutic efficacy was observed when the mAb therapy was started at a later tumor-bearing stage (day 17).In a bilateral tumor inoculation model, this combination therapy achieved systemic therapeutic effects and suppressed the growth of mAb-untreated tumors.These results suggest that intermittent immunochemotherapy using CP and GEM could retain the therapeutic potential of anti-CD137 mAb that is normally impaired during the late tumor-bearing stage.
Affiliation: Department of Experimental Animals, Center for Integrated Research in Science, Shimane University, Izumo, Japan.Show MeSH
Related in: MedlinePlus
Mentions: We next examined the antitumor effect of the combination of anti-CD137 mAb and intermittent chemotherapy with low-dose CP and GEM (Fig.3a,b). Intermittent chemotherapy on days 10 and 18 suppressed tumor growth significantly, and 3 of the 16 mice were cured by chemotherapy alone. When the intermittent chemotherapy was followed by local anti-CD137 mAb therapy, more significant tumor regression was observed; 8 of the 16 mice were cured. Although some mice were not cured, they showed continuous growth suppression, so-called “stable disease,” for more than 2 weeks after the last Ab therapy.
Affiliation: Department of Experimental Animals, Center for Integrated Research in Science, Shimane University, Izumo, Japan.